Treatment of patients with breast cancer or gastrointestinal cancer and chemotherapy-induced polyneuropathia with whole body vibration (Galileo technology)

Not Applicable

Recruiting

Conditions: Chemotherapy induced polyneuropathy
G62
Other polyneuropathies

Registration Number: DRKS00006181

Lead Sponsor: Klinik für Tumorbiologie

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 50

Inclusion Criteria

Inclusion criteria
• patients with breast cancer or gastrointestinal cancer and Chemotherapy-induced Polyneuropathy
• rehabilitation planed for at least 3 weeks
• no further chemotherapy is planed
• age = 18 years
• perfomance status: Karnofsky-Index = 80%
• average of life expectancy of at least 4 months
• patient is able (i) to understand the being, importance and range of the study and (ii) to give the approval for the participation in the study
• signed informed consent

Exclusion Criteria

Exclusion criteria
• diseases which are able to endangering the safety of the patients or which can influence the validity of the study
• instable bone metastases or osteoporosis
• myocardial infarction = 6 months, angina pectoris (when the angina pectoris is instable
or starts = 3 months)
• heart disease (NYHA = III)
• uncontrolled hypertension
• acute thrombosis
• severe acute infection
• acute discopathia, acute tendinopathia
• acute inflammation of the hinges or of the movement apparatous
• acute hernia
• recurring Renal or Bilious colic
• wounds fresh or being cured badly or ulcera or bone fractures
• endoprosthesis or insufficient osteosynthetische supply
• acute bleeding, gastrointestinale hemorrhage = 4 weeks
• pregnancy
• greater surgical intervention, difficult trauma = 4 weeks
• heavy neuropathia (PNP Score = 7)
• akute rheumatoid arthritis
• epilepsy

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
polyneuropathic disorders<br><br>Method: FACT/GOG-Ntx-Questionaire (%): Detection of subjective Symptoms<br><br>Time of investigation: (T0) initial, (T1) after 3 weeks of treatment, (T2) 3 months after the start of the trail

Secondary Outcome Measures